Article in Atherosclerosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Mouaz H Al-MallahHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, USA. Electronic address: mal-mallah@houstonmethodist.org.
Fabien HyafilDepartment of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm 1148, Université Paris Diderot, Paris, France.
Gaetano SantulliDepartment of Medicine (Cardiology), Wilf Family Cardiovascular Research Institute, USA; Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), The "Norman Fleischer" Institute for Diabetes and Metabolism (FIDAM), New York, NY, USA.
Assistance Publique – Hôpitaux de Paris · FRIcahn School of Medicine at Mount Sinai · USMethodist Hospital · US
Funding
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STREAMSON C CHUA · 2015 to 2026
$27.7M
REGULATION OF THE INSULIN RECEPTOR KINASER01DK033823 · NIDDK · UNIVERSITY OF IOWA · PI KURLAND, IRWIN JACK, PESSIN, JEFFREY E. · 1986 to 2022
$6.7M
Functional role of IP3 receptors in the regulation of cardiac myofibroblastsR01HL146691 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2019 to 2023
$2.1M
Beta Cell Intracellular Calcium and DiabetesR01DK123259 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2020 to 2023
$1.7M
Targeting intracellular calcium leak as novel therapy for diabetesR00DK107895 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SANTULLI, GAETANO · 2018 to 2020
AtherosclerosisDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsPlaque, AtheroscleroticAnimalsDipeptidyl Peptidase 4Fluorodeoxyglucose F18InflammationLinagliptinMiceDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsFluorodeoxyglucose F18LinagliptinAtherosclerosisDiabetesLinagliptin
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed. · full record | OpenQuestion